--- title: "ApoB Home Test Kit — Evidence, Benefits & Where to Buy | Magellan" description: "ApoB Home Test Kit — Apolipoprotein B (apoB) is the primary structural protein of the atherogenic lipoproteins, with exactly one apoB molecule carried on…" url: "https://magellanlongevity.com/p/140.md" canonical: "https://magellanlongevity.com/p/140.html" html: "https://magellanlongevity.com/p/140.html" type: "product" section: "Diagnostics & Epigenetic Tests" evidence_grade: "Measurement tool" evidence_tier: "tool" citations: 18 product_id: 140 price_usd: 79 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" license: "Educational content — not medical advice" --- # ApoB Home Test Kit [Home](https://magellanlongevity.com/) › [Diagnostics & Epigenetic Tests](https://magellanlongevity.com/c/2.md) › ApoB Home Test Kit **HTML version:** https://magellanlongevity.com/p/140.html · **In the Magellan app:** https://magellanlongevity.com/#/product/140 ## Key facts | Field | Value | | --- | --- | | Product | ApoB Home Test Kit | | Category | [Diagnostics & Epigenetic Tests](https://magellanlongevity.com/c/2.md) | | Evidence grade | Measurement tool (B) | | Peer-reviewed citations | 18 | | Typical listed price | $79.00 (check the live price) | | Where to buy | [Search Amazon](https://www.amazon.com/s?k=ApoB%20Home%20Test%20Kit&tag=magellanlong-20) | | Catalog ID | 140 | ## What it is Apolipoprotein B (apoB) is the primary structural protein of the atherogenic lipoproteins, with exactly one apoB molecule carried on each particle of low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), intermediate-density lipoprotein, chylomicron remnants and lipoprotein(a). Because of this one-to-one relationship, a blood apoB concentration directly counts the total number of cholesterol-carrying, plaque-forming particles in the circulation, whereas an LDL-cholesterol value estimates only the cholesterol mass those particles carry. An apoB test therefore reports particle number rather than cholesterol content, and the two can diverge ("discordance") in people with diabetes, obesity, high triglycerides or metabolic syndrome. ## Its role in longevity Large Mendelian randomization studies, prospective cohorts and meta-analyses — in one pooling of 233,455 people apoB was the strongest lipid risk marker, about 12% better than LDL-cholesterol — indicate that apoB is the predominant lipid trait driving atherosclerotic cardiovascular disease, and that the particle number captured by apoB predicts myocardial infarction and residual risk more accurately than LDL-cholesterol or non-HDL-cholesterol, especially in statin-treated and discordant patients. In 2019 the European Society of Cardiology/European Atherosclerosis Society judged apoB a more accurate risk marker than LDL-C, and a 2024 National Lipid Association expert consensus recommends measuring it to refine risk, particularly with diabetes, obesity or high triglycerides. The evidence is not uniform: some cohorts (e.g., in women) found non-HDL-cholesterol as good as apoB, remnant cholesterol can add risk beyond apoB, and in established coronary disease and the general population very low apoB tracks with higher mortality through reverse causation (malnutrition, illness), producing U-shaped or "paradoxical" associations. Guidelines still treat LDL-C as the primary target and do not yet recommend routine apoB screening for everyone, and apoB is a risk marker rather than a treatment. This evidence concerns apolipoprotein B as a biomarker and the biology of atherogenic particles, not any specific commercial home test kit. ## Evidence grade: Measurement tool - **What the grade means:** Graded as an instrument: how accurately it measures, and whether measuring it changes anything. - **Dose used in studies:** Once to find out where you stand, then repeat about 8-12 weeks after any deliberate change - a statin, a real diet change, meaningful weight loss. Fasting is not required for ApoB. Stick to one lab, because between-lab differences are larger than the changes you are looking for. - **What this grade does not say:** ApoB counts atherogenic particles rather than the cholesterol inside them, and where the two disagree the particle count is the better guide to risk - that part is well supported and is why several lipid guidelines now list it as a preferred target. Whether a mailed finger-stick delivers that number reliably is a separate question, and the honest answer is partly. A dried blood spot ApoB assay has been shown to correlate closely with a plasma reference method, but that work was done on laboratory-prepared spots from venous blood with a haematocrit correction applied, not on cards collected at a kitchen table and posted in July - collection technique, spot volume and haematocrit are all real sources of error nobody is controlling at your end. Treat a home ApoB as a screening number that tells you roughly which band you are in, and if it lands high, the next step is a venous panel through a clinician rather than a second kit. ## In the news - **Is an apoB test a better way to check your cholesterol?** — Harvard Health 2025 [Read it](https://www.health.harvard.edu/heart-health/is-an-apob-test-a-better-way-to-check-your-cholesterol) > Because the apoB test reveals the total number of atherogenic particles in the blood, it provides a better picture of a person's risk of cardiovascular disease. - **Apo B Test** — Cleveland Clinic 2023 [Read it](https://my.clevelandclinic.org/health/diagnostics/24992-apolipoprotein-b-test) > Researchers have found that measuring Apo B may predict heart and blood vessel disease risk better than a lipid panel test. - **Is this blood test a better predictor of heart disease than LDL cholesterol?** — NBC News 2026 [Read it](https://www.nbcnews.com/health/heart-health/blood-test-heart-disease-protein-apob-ldl-cholesterol-rcna256520) > Since each one of the harmful particles contains one apoB molecule, testing for it essentially captures the overall number of harmful plaque-producing compounds. ## The research Peer-reviewed studies on the active compound. Quotes are verbatim from the cited abstract. Research describes the active mechanism and is not a claim about this specific product. ### Cited studies 1. **Evidence: Apolipoprotein B particle count** J Am Coll Cardiol 2021 · [PMID 33736827](https://pubmed.ncbi.nlm.nih.gov/33736827/) · [DOI 10.1016/j.jacc.2021.01.027](https://doi.org/10.1016/j.jacc.2021.01.027) > apoB is a more accurate marker of all-cause mortality risk than LDL cholesterol 2. **Physiological Bases for the Superiority of Apolipoprotein B as a Marker of Cardiovascular Risk** J Am Heart Assoc 2022 · [PMID 36216435](https://pubmed.ncbi.nlm.nih.gov/36216435/) · [DOI 10.1161/JAHA.122.025858](https://doi.org/10.1161/JAHA.122.025858) > the total number of apoB particles determines cardiovascular risk 3. **Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in cardiovascular disease risk assessment** Pathology 2018 · [PMID 30595507](https://pubmed.ncbi.nlm.nih.gov/30595507/) · [DOI 10.1016/j.pathol.2018.11.006](https://doi.org/10.1016/j.pathol.2018.11.006) > non-HDL-cholesterol and apoB are superior to LDL-cholesterol in predicting cardiovascular risk 4. **Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.** JAMA Cardiol 2022 · [PMID 34773460](https://pubmed.ncbi.nlm.nih.gov/34773460/) · [DOI 10.1001/jamacardio.2021.5083](https://doi.org/10.1001/jamacardio.2021.5083) > However, when assessed together, only apoB was associated (adjusted hazard ratio [aHR] per 1 SD, 1.27; 95% CI, 1.15-1.40; P < .001). Similarly, only apoB was associated with MI in the secondary prevention cohort. 5. **Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis.** PLoS Med 2020 · [PMID 32203549](https://pubmed.ncbi.nlm.nih.gov/32203549/) · [DOI 10.1371/journal.pmed.1003062](https://doi.org/10.1371/journal.pmed.1003062) > In multivariable MR, only apolipoprotein B (OR 1.92; 95% CI: 1.31-2.81; P < 0.001) retained a robust effect, with the estimate for LDL cholesterol (OR 0.85; 95% CI: 0.57-1.27; P = 0.44) reversing and that of triglycerides (OR 1.12; 95% CI: 1.02-1.23; P = 0.01) becoming weaker. 6. **Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention.** Eur Heart J 2024 · [PMID 38700053](https://pubmed.ncbi.nlm.nih.gov/38700053/) · [DOI 10.1093/eurheartj/ehae258](https://doi.org/10.1093/eurheartj/ehae258) > None of the residuals of LDL-C, non-HDL-C, or of log triglycerides remained significant when apoB was included in the model. 7. **Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study.** Eur Heart J 2021 · [PMID 34293083](https://pubmed.ncbi.nlm.nih.gov/34293083/) · [DOI 10.1093/eurheartj/ehab432](https://doi.org/10.1093/eurheartj/ehab432) > In ASCVD-free individuals, elevated RC levels were associated with ASCVD independent of traditional risk factors, LDL-C, and apoB levels. 8. **Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis.** J Am Coll Cardiol 2024 · [PMID 38233012](https://pubmed.ncbi.nlm.nih.gov/38233012/) · [DOI 10.1016/j.jacc.2023.10.039](https://doi.org/10.1016/j.jacc.2023.10.039) > From these data, we estimate that the atherogenicity of Lp(a) is approximately 6-fold (point estimate of 6.6; 95% CI: 5.1-8.8) greater than that of LDL on a per-particle basis. 9. **Update on the detection and treatment of atherogenic low-density lipoproteins.** Curr Opin Endocrinol Diabetes Obes 2013 · [PMID 23422241](https://pubmed.ncbi.nlm.nih.gov/23422241/) · [DOI 10.1097/MED.0b013e32835ed9cb](https://doi.org/10.1097/MED.0b013e32835ed9cb) > By contrast, a meta-analysis of published prospective studies demonstrated that non-HDL-C was superior to LDL-C, and apoB was superior to non-HDL-C. 10. **Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.** J Clin Lipidol 2015 · [PMID 26228670](https://pubmed.ncbi.nlm.nih.gov/26228670/) · [DOI 10.1016/j.jacl.2015.05.003](https://doi.org/10.1016/j.jacl.2015.05.003) > Overall, 64% of statin users were at goal for LDL-C, 63% were at goal for non-HDL-C, but only 52% were at goal for apoB. 11. **Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes.** Diabetes Care 2004 · [PMID 15277429](https://pubmed.ncbi.nlm.nih.gov/15277429/) · [DOI 10.2337/diacare.27.8.1991](https://doi.org/10.2337/diacare.27.8.1991) > Non-HDL cholesterol and apoB are more potent predictors of CVD incidence among diabetic men than LDL cholesterol. 12. **Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein.** J Intern Med 2010 · [PMID 21129046](https://pubmed.ncbi.nlm.nih.gov/21129046/) · [DOI 10.1111/j.1365-2796.2010.02323.x](https://doi.org/10.1111/j.1365-2796.2010.02323.x) > The age- and sex-adjusted hazard ratio (HR) was 1.37 [95% confidence interval (CI), 1.26-1.48] for the apoB/apoA-I ratio and 1.24 (95% CI, 1.18-1.29) for the TC/HDL-C ratio (both P < 0.001). 13. **Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.** JAMA 2005 · [PMID 16030277](https://pubmed.ncbi.nlm.nih.gov/16030277/) · [DOI 10.1001/jama.294.3.326](https://doi.org/10.1001/jama.294.3.326) > Non-HDL-C and the ratio of total cholesterol to HDL-C were as good as or better than apolipoprotein fractions in the prediction of future cardiovascular events. 14. **Paradoxical Association Between Baseline Apolipoprotein B and Prognosis in Coronary Artery Disease: A 36,460 Chinese Cohort Study.** Front Cardiovasc Med 2022 · [PMID 35146010](https://pubmed.ncbi.nlm.nih.gov/35146010/) · [DOI 10.3389/fcvm.2022.822626](https://doi.org/10.3389/fcvm.2022.822626) > Malnutrition and bilirubin mainly mediate the ApoB paradox. Increased ApoB concentration remained linearly associated with an increased risk of long-term all-cause mortality. 15. **Low apolipoprotein B and LDL-cholesterol are associated with the risk of cardiovascular and all-cause mortality: a prospective cohort.** Ann Med 2025 · [PMID 40642933](https://pubmed.ncbi.nlm.nih.gov/40642933/) · [DOI 10.1080/07853890.2025.2529565](https://doi.org/10.1080/07853890.2025.2529565) > Low apoB and LDL-cholesterol levels were associated with heightened all-cause and cardiovascular mortality risk in the general population. Conversely, high apoB and low LDL-cholesterol levels did not correlate with increased mortality risk. 16. **Relationship between serum apolipoprotein B and risk of all-cause and cardiovascular disease mortality in individuals with hypertension: a prospective cohort study.** BMC Cardiovasc Disord 2024 · [PMID 38789961](https://pubmed.ncbi.nlm.nih.gov/38789961/) · [DOI 10.1186/s12872-024-03949-1](https://doi.org/10.1186/s12872-024-03949-1) > In the US hypertensive population, serum Apo B levels were U-shaped and correlated with ACM and CVM risk, with the lowest risk at 100 mg/dL. 17. **A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.** Circulation. Cardiovascular quality and outcomes 2011 · [PMID 21487090](https://pubmed.ncbi.nlm.nih.gov/21487090/) > In a meta-analysis of 233,455 people, apoB was the strongest lipid risk marker (relative-risk ratio 1.43 vs 1.34 for non-HDL-C and 1.25 for LDL-C), beating LDL-C by 12%. 18. **Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association.** Journal of clinical lipidology 2024 · [PMID 39256087](https://pubmed.ncbi.nlm.nih.gov/39256087/) > National Lipid Association expert consensus recommends apoB measurement to refine cardiovascular risk, especially in people with diabetes, obesity, high triglycerides or discordant LDL-C. ## Where to buy [Search Amazon for ApoB Home Test Kit](https://www.amazon.com/s?k=ApoB%20Home%20Test%20Kit&tag=magellanlong-20) — affiliate search link. ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"ItemPage","@id":"https://magellanlongevity.com/p/140.html#page","url":"https://magellanlongevity.com/p/140.html","name":"ApoB Home Test Kit","description":"Apolipoprotein B (apoB) is the primary structural protein of the atherogenic lipoproteins, with exactly one apoB molecule carried on each particle of…","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/p/140.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Diagnostics & Epigenetic Tests","item":"https://magellanlongevity.com/c/2.html"},{"@type":"ListItem","position":3,"name":"ApoB Home Test Kit","item":"https://magellanlongevity.com/p/140.html"}]},{"@type":"Product","@id":"https://magellanlongevity.com/p/140.html#product","name":"ApoB Home Test Kit","category":"Diagnostics & Epigenetic Tests","url":"https://magellanlongevity.com/p/140.html","description":"Apolipoprotein B (apoB) is the primary structural protein of the atherogenic lipoproteins, with exactly one apoB molecule carried on each particle of low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), intermediate-density lipoprotein, chylomicron remnants and lipoprotein(a).…","additionalProperty":[{"@type":"PropertyValue","name":"Evidence grade","value":"Measurement tool"}],"offers":{"@type":"Offer","priceCurrency":"USD","price":"79.00","url":"https://www.amazon.com/s?k=ApoB%20Home%20Test%20Kit&tag=magellanlong-20","availability":"https://schema.org/InStock"}}]} ``` ## Related on Magellan Longevity - [Grip-Strength Dynamometer](https://magellanlongevity.com/p/153.md) — Across large prospective cohorts and meta-analyses, lower grip strength is consistently associated with… - [Saliva Cortisol Stress Test](https://magellanlongevity.com/p/149.md) — Across large studies, dysregulated cortisol patterns track with worse health: a meta-analysis found flatter… - [GGT Liver-Health Test](https://magellanlongevity.com/p/156.md) — Large prospective cohorts and meta-analyses consistently link higher serum GGT, even within the reference… - [Fasting Insulin / HOMA-IR Kit](https://magellanlongevity.com/p/145.md) — Higher fasting insulin and HOMA-IR reflect greater insulin resistance, a central feature of metabolic… - [hs-CRP Inflammation Test](https://magellanlongevity.com/p/142.md) — Across large prospective cohorts and meta-analyses, higher hs-CRP is consistently associated with increased… - [All Diagnostics & Epigenetic Tests](https://magellanlongevity.com/c/2.md) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).